SEARCH WITHIN CONTENT
VOLUME 9 , ISSUE 2 ( December, 2018 ) > List of Articles
Krishna Kripal, Senthil Rajan, Kavita Chandrasekaran, Thaslim Fathima
Keywords : Concentrated growth factor, Furcation involvement, Hydroxyapatite crystals, Periodontal disease
Citation Information : Kripal K, Rajan S, Chandrasekaran K, Fathima T. Treatment of Grade II Mandibular Furcation Defects by Concentrated Growth Factors and Hydroxyapatite Bone Substitute (Sybograf®): A Case Report. J Health Sci Res 2018; 9 (2):61-65.
License: CC BY-NC 4.0
Published Online: 01-06-2019
Copyright Statement: Copyright © 2018; The Author(s).
Aim: This case report attempts an evaluation of the clinical and radiographic outcome of concentrated growth factors (CGF) along with nanohydroxyapatite bone substitute in considering grade II mandibular furcation defects. Background and objectives: Periodontal disease, if not interfered, will headway further with attachment loss, adequate enough to have a consequence on the bifurcation or trifurcation of multirooted teeth. There is a paucity of studies comparing the effects of CGF and nanohydroxyapatite crystals bone substitute in furcation defects. Case discussion: A male patient, 66 years old, had visited the outpatient department of periodontology, with a chief complaint of sensitivity in the lower left back tooth region for the past few months. The probing depth as measured by UNC-15 probe was 5 mm mesiobuccal, 10 mm midbuccal, 5 mm distobuccal and 5 mm midlingual. The furcation defect was filled using an appropriate combination of CGF and bone graft material (Sybograf). The flap was sutured with 3–0 silk suture to obtain primary closure. Conclusion: The results have shown significant improvement in the gingival index and probing pocket depth (horizontal and vertical). There was a significant amount of bone fill also that was evident radiographically. Clinical significance: The current case report boons a new approach for the treatment of grade II mandibular furcation defects through a collective approach of CGF and nanohydroxylapatite bone substitute.